Member Info for B2HS2L

This morning Simon Bennett still features on Avacta's Leadership team web page.

My question is, now that NED's of this status have been attracted to the board, what is SB's status going forward, now he's active with AS.

I sense the hand of Shaun Chilton in recruiting these two NED's

Has SB's role changed / shrunk

"Hope" is not a strategy

I think you mean - I hope they've got something better than LFT's to hand.

'legitimate questions marks' - You'd know all about those at the rate of umpteen a post.

Calm down? -

We're elated you pests haven't got a clue what the next FUD angle is going to be.

We'll know you've lost it if LFT's get a mention.

No posts this morning is proof you have a negative agenda here.

Wyndrum / Touk - No posts

Thorn = 1 negative post

Must be regrouping.

I hope they've got something better than LFT's to hand.

Timster, - Distributed by Coris in Europe - ha ha.

Opti_

"bigger picture is the fact that there is no point in bringing in people to negotiate the commercials if there is no-one interested in talking to you about them."

And Simon Bennett seems busy with ALastair now, - too busy to do the negotiating. - Has he gone completely, - unannounced.

Grok queery:

FYI

David Bryant and Richard Hughes have today been appointed NED's at Avacta Therapeutics.

Have the two worked before elsewhere?

Response:

I couldn’t find any definitive evidence in the available information that David Bryant and Richard Hughes have previously worked together at the same organization or on specific projects prior to their appointments as Non-Executive Directors (NEDs) at Avacta Therapeutics. The search results and available data do not explicitly mention any shared professional history between the two individuals at other companies or in other capacities.

However, here’s what I can confirm based on the available information:

Richard Hughes is referenced in connection with Avacta through a 2020 partnership involving Medusa19, a company he co-founded with Mahmud Kamani, which secured an exclusive distribution agreement with Avacta for a COVID-19 home saliva test. Hughes was noted as a former non-executive director of Boohoo Group plc at the time.

No specific professional background for David Bryant is provided in the search results, and there is no mention of him working with Richard Hughes in any capacity prior to their NED appointments at Avacta Therapeutics.

The search results focus heavily on Avacta’s leadership, appointments, and partnerships but do not indicate any prior collaboration between Bryant and Hughes at other organizations.

Https://tinyurl.com/35a55f28 😏

Apologies, there are two occasions on page three where the timeline states 'AVA6000 partnering opportunity'.

Https://www.research-tre*.c o m/

also -

https://*********************/notearticle/article?researchnoteid=33_15e65d50-754b-426d-932b-96392a6ff525&whitelabelcompanyid=gb00byyw9g87&clearcache=false

trinity delta report 18.03.2025 (td don't stray far from info or confirmations provided by avct) :

pages 2 & 3 - both display ava6000 partnering opportunity q4 2025 - q1 2026 on the timeline.

++++

i hope cc & sb will name a date that all unsigned deals will be complete and in her safe by mid december, and that we finalise a partner asap in 2026.

coris deal required soonest sb please, even if it's peanuts.

we can then say we are truly a therapeutics company with no diagnostic exposure, which should please quite a few parties. 😉😏

i think we need to be on nasdaq soonest.

Question 4:

Based on the safety data so far, even if phase 2 for some reason shows that AVA6000 is no more effective than conventional Doxorubicin, can it still be assumed that AVA6000 will replace doxorubicin in chosen indications and therefore already be classed as 'successful'?

Answer 4

It’s a good debate. There are multiple pathways by which a drug can be approved, this question is referring to one that is called essentially non-inferiority, meaning that the efficacy is the same but the safety is better. In order to get a drug approved though using this path, it is a much larger trial. The statistics to prove that non-inferiority are looking at a much larger trial longer route to approval as well as a much more expensive trial. A more favourable scenario for a drug like AVA6000 is to show superior efficacy. This is one of the reasons that we’re spending this bit of time and resource on a very careful selection of what the phase two indication is. We’re looking for a shorter more effective trial for AVA6000 with evidence of superiority.

Question 12:

If the pipeline is going to be revealed soon, does the Board have plans on how this pipeline will be funded? Won’t AVA6000 need more funding?

Answer 12

If we set aside diagnostics for a minute which we have already said we are going to be divesting, we are a pre-revenue biotech company, with an incredibly promising platform. We’d like to be able to take the opportunity in the pipeline to take a couple more shots on goal. You’ve seen our financial results today our spend numbers and the drug development requires at risk investment. The reason we do this is because we believe in the impact on the pipeline, and so this means as a company we need a sustainable funding strategy that’s going to allow us to progress the pipeline to a later stage of development where we can either have those partnerships. To date we have been raising money on AIM or borrowing money in the form of the convertible note. We are also looking at non-dilutive options such as collaborations that I touched on in that first comment. But we are going to be looking now at deep specialist health care funds in the US, including the option of the dual listing and we have to recognise that the UK and indeed the global context for raising money is still fragile, it’s still a bit uncertain, and so the reality is that we are going to need a combination of these factors for the long-term strategy.

Suggest reviewing page 1 & 2 of this Turner Pope Document:

https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/94f81303-3e77-d614-8e6b-6cd5bf6b3b9b/AvactaGroupplc_2_10_2024_FINAL_BG.01.pdf

For me BP need to see the successful Ph1b results and list their remaining concerns.

As in 'Let the Greyhounds see the Hare'.

Some of CC's business utterings are lost in presentations that have no transcript.

They are available, but only on video, and then a search is required to find applicable tracts.

Here are some transcripts I can provide to lighten the mood after doom-mongers have had their say.

Transcription of Investor Meet Avacta Presentation 30.09.2024 Q/A session

https://www.investormeetcompany.com/meetings/investor-presentation-722

YouTube reference - https://www.youtube.com/watch?v=IROUElHyJfw&t=305s

Question 2:

It seems that it has been hard for the company to strike a deal – why is this? What is the complexity here in getting a licensing deal done?

Answer 2

As you mention thinking back to our last question, striking a deal isn’t hard if we are willing to give away part of our intellectual property. Giving away – this is important – the time that our scientists need and the gain here in a quick deal that we can do in phase 1 would be to put a molecule in a drug in another party’s pipeline. That kind of deal we can strike now, but currently with our board’s support we have decided that we will focus on the right deal at the right time. A deal that will surround either our own pipeline assets such as AVA6000, or a co-development deal in which case the novel medicine will be in our pipeline as well as the potential partners pipeline. We have decided that a quick deal to put a precision medicine in another company’s pipeline is not one that we will pursue. So these can take longer, they need more clinical data even into phase 2, and perhaps even a second asset in the clinic. So stay tuned, we are looking forward to updating you on importantly that second asset in the clinic.

Continued

For the avoidance of doubt

Doesn't sound like many have referred to this statement:

https://www.investopedia.com/terms/g/goingconcern.asp

Definition

A going concern is a business that is financially stable and is expected to continue operating indefinitely.

What Is Going Concern?

"Going concern" is a commonly used term for a healthy business but it also is a core accounting principle.

In accounting, a company is either a going concern or is not financially viable. This determination, based on a study of the company's financials, is generally understood to be good for at least 12 months.

Thus, the label going concern indicates that a company is making enough money to stay afloat for the foreseeable future or until there is evidence to the contrary.

Key Takeaways

If a company is a going concern, certain expenses and assets may be deferred in financial reports.

If a company is no longer a going concern, it must start reporting certain additional information in its financial statements.

Negative signals that a company is no longer a going concern include denial of credit, continuing losses, and potentially expensive lawsuits.

An auditor must insert a going concern opinion in the audit report if there are doubts about the financial viability of a company.

Going Concern

Investopedia / Eliana Rodgers

Understanding Going Concern

Accountants use going concern principles to decide what types of reporting must be recorded on a company's financial statements.

Companies that are going concerns may defer reporting long-term assets at current value or liquidating value, and instead report them at cost.

Accountants who conclude that a company is a going concern generally believe the company is using its assets wisely and does not have to liquidate anything to meet its financial obligations.

'the likely future cash position would have been very clearly known and understood 9 months ago' 9 months ago = 22 August 2024.

RNS 21 Oct 2024 Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

'Avacta plans to leverage these insights to further enhance its pre|CISION® platform reach through the identification of the full addressable patient populations for its clinical programs. Tempus's analytical support and computational biology experts will collaborate in the data analysis with the Avacta team.'

No mention of cost attached to those services, but they won't be minimal, and Avacta have been gold card holders according to CC and MM recently.

CC mentions BP always wanting more and more data see below

BoD may not have had this event on their radar in August.

++++

However, cash runway announced here:

RNS 07.03.2025 - Following the divestment of Launch Diagnostics, the Company's cash runway will extend into Q1 2026.

RNS 25.03.2025 - Avacta Announces Completion of the Sale of Launch Diagnostics - No cash runway update.

Also 30.09.2024 Transcription of Investor Meet Avacta Presentation

Q 1:

..When will the company finally deliver on the multiple promises made over the past year and announce a license deal.

A 1:

We have been working hard on this over the last few months. We – the management team - have met many companies, US, Europe, Asia.

We have still early data in our Phase 1 trial with 57 patients treated. We should also remember why we are interested in such deals / collaborations. There are two reasons, the first is validation from well-known players in the oncology space, and second secure some upfront non-dilutive funding. Recall the amount of funding received in the form of upfront payment to execute on the deal is going to be based on the stage of the deal and the asset, so for example a pre-clinical deal with another company’s medicine and the precision technology won’t be worth near to what an asset with phase 2 data would be worth. We have spoken to a number of smaller and mid-sized biotech’s who can move very quickly and are interested to collaborate at an early stage, but whilst we could do some deals with these types of companies, often they are not going to give us the validation that we would really like. To be honest we may even help them more in this respect than they help us as the medicine would be in their pipeline. Their ability to provide meaningful funding is somewhat limited. We have also spoken to large pharma companies which would partner entire assets or for example AVA6000 and can provide the validation we are interested in, as well as the meaningful financial terms, but these larger pharmaceutical companies tend to work very slowly, - want more data, with these types of deals.. Hence RNS 21.10.24 Tempus

There are no such things as accurate weather forecasters.

We refer our local weather presenter as Pinocchio.

Nineteen I think yesterday, - but not an exceptional day for you.

'The reason I bore you all to death' - is because you are boring, know you are boring, and think it more than likely we will respond to boring posts, even if negatively.

Give yourself a rest, go for a walk, you know, do what watching prescribes, but post less boring s*ite.

Another stand out found here:

https://www.turnerpope.com/investor-evenings/webinars/

CC 'exetecan can 'overcome' treatment resistance caused by prior treatment using another Topo1 inhibitor.'

'The very existence of Simon Bennett is gaslighting personified.'

+++

You have my interest. - How would you expect a person performing the business manager role to perform those duties?

What is in his list of accountabilities?

AFAIK he does not have a shareholder facing role, and what he pursues and reports is for the boards ears and eyes only.

Easy for shareholders to think he no place in the big picture.

If he was not performing, with the cash runway ending Jan 2026, he might be for the high jump soon.

If his efforts were meeting with success, CC's safe would be bulging with a choice of unsigned deals. She's gonna need a bigger safe.

Esspekay, BV - Quote from

Investor Meet Transcript 30.04.2024

Presentation given by CC as AS resigned today and CC becomes CEO tomorrow.

Presentation found here: https://www.youtube.com/watch?v=17Rj2hCSfUI&t=651s

LL -

Those BP with access to the data room will be seeing their ADC investment further threatened as more data arrives from 6K 1b each month.

I hope it is becoming clear for multiple reasons why ADC development is becoming old school before their eyes.

Watching and waiting, BP will be reviewing what they can afford to do short term ie after 1b trial announcements.

The cost of an Avacta buyout, should they progress projects in clinic to successful phase 2 completion, will cause many BP to strongly consider an earlier Avacta purchase.

Waiting to purchase when projects have become more mature is an unattractive, unsavoury option.

Many BP will want to replenish their projects locker sooner rather than later.

Who is willing to go with this very successful team after phase 1b announcements, a higher level of risk than some would be happy with.